Cadherin 1 (CDH1) Antikörper

Antigen: Cadherin 1 (CDH1)

Synonyme: cdh1, E-cadherin, si:dz180o5.2, dZ71B9.1, si:dz180o5.1, CDH1, uvo, lcam, E-Cad, XBcad, l-cam, xcdh1, cdhc-A, xb-cad, XTCAD-1, c-cadherin, cadherin-1, uvomorulin, XB-cadherin, UVO, CDHE, ECAD, LCAM, Arc-1, CD324, HPT1, CDH16, HPT-1, FLJ26931, MGC138218, MGC142024, cad17, hpt1, cdh16, hpt-1, LI-cadherin, cadherin-17

Klonalität: Monoklonal (NCH-38 4)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (IHC), Immunhistochemie (IHC)

Zertifikate: ISO 9001:2008, ISO 13485:2003

Anbieter: Dako

Produktnummer: ABIN370657

Produktbeschreibung

Weitere Bezeichnung: E-Cadherin

Immunogen: E-cadherin (uvomorulin) and GST recombinant protein 4

Isotyp: IgG1, kappa chain  (Passende Sekundärantikörper)

Klon: NCH-38 4

Beschreibung: Synonyms E-CD, uvomorulin, L-CAM, Arc-1, or cell-CAM 120/180 1-3 Summary and explanation E-cadherin is a 120 kD transmembrane cell adhesion molecule. The gene has been localized on chromosome 16q22.1. In its extracellular domain, E-cadherin is involved in cell-cell adhesion through calcium-regulated homophilic interactions, whereas in its intracellular domain, E-cadherin connects to the actin cytoskeleton via catenins. E-cadherin has a significant function in intercellular adhesion of epithelial cells, the establishment of epithelial polarization, glandular differentiation, and stratification. It is localized mainly in the adherens junctions and concentrates the urokinase plasminogen and the epidermal growth factor receptor to cell contact sites. 5,6 Down-regulation of E-cadherin expression has been observed in a number of carcinomas and is usually associated with advanced stage and progression. 5-8

Spezifität: Anti-E-cadherin, NCH-38 recognizes the 120 kD mature form and 82 kD fragment of E-cadherin in Western blots of A431 cells lysates. 4

Synonyme: cdh1, E-cadherin, si:dz180o5.2, dZ71B9.1, si:dz180o5.1, CDH1, uvo, lcam, E-Cad, XBcad, l-cam, xcdh1, cdhc-A, xb-cad, XTCAD-1, c-cadherin, cadherin-1, uvomorulin, XB-cadherin, UVO, CDHE, ECAD, LCAM, Arc-1, CD324, HPT1, CDH16, HPT-1, FLJ26931, MGC138218, MGC142024, cad17, hpt1, cdh16, hpt-1, LI-cadherin, cadherin-17

Anwendungen

Applikationshinweise: Monoclonal Mouse Anti-Human E-cadherin, clone NCH-38 (Anti-E-cadherin, NCH-38) is intended for laboratory use to identify qualitatively by light microscopy E-cadherin positive cells in normal and neoplastic tissues using immunohistochemical (IHC) test methods. The clinical interpretation of any positive staining or its absence should be complemented by morphological and histological studies with proper controls. Evaluations should be made within the context of the patient's clinical history and other diagnostic tests by a qualified individual. Paraffin Sections Anti-E-cadherin, NCH-38 can be used on formalin-fixed, paraffin-embedded tissue sections. The deparaffinized tissue sections must be treated with heat prior to the IHC staining procedure. Target retrieval involves immersion of tissue sections in a pre-heated buffer solution and maintaining heat, either in a water bath (95-99 °C), a steamer (95-99 °C) or an autoclave (121 °C) . For greater adherence of tissue sections to glass slides, the use of Silanized Slides (code S3003) is recommended. Target Retrieval Solution (code S1700) or 10x Concentrate (code S1699) is recommended using a 20-minute heating protocol. Cryostat Sections and Cell Smears Anti-E-cadherin, NCH-38 can be used for labeling acetone-fixed cryostat sections or fixed cell smears. Target or antigen retrieval is not required. Follow the procedure for the detection system selected. Staining interpretation The cellular staining pattern for anti-E-cadherin, NCH-38 is membranous and/or cytoplasmic. Normal Tissues E-cadherin expression has been demonstrated by immunohistochemistry in (40/40) normal urothelium specimens (frozen and paraffin). 8 Normal human mammary gland has been found to strongly express E-cadherin in the intercellular borders of the luminal cells of both the interlobular ducts and the intralobular terminal ducts and ductules but expression was much weaker in myoepithelial cells of ducts and ductules (frozen and paraffin). 10 Squamous epithelial cells in esophagus were found to be strongly immunoreactive (15/15) on cell-cell boundaries, except in the most superficial keratinizing layer. Also, E-cadherin was immunolocalized in normal gastric mucosa at the cell-cell boundaries of the foveolar epithelia as well as in gastric crypts and deep gastric glands (frozen and paraffin). 1, 2 In normal endometrium, almost all the glands revealed strong E-cadherin expression (frozen). 11 E-cadherin immunoreactivity has been localized in normal skin along the lateral and upper surfaces of basal keratinocytes at intercellular borders but was absent at the basal cell surface. In the suprabasal layers of skin, E-cadherin expression was localized uniformly around the periphery of the cells, however no expression was seen in the superficial corneal layer. The adnexal structures of skin also demonstrated E-cadherin immunoreactivity including membrane staining of the outer root sheath cells (the inner sheath cells were negative), acinar germinative cells in the sebaceous glands and sweat gland cells of skin. No E-cadherin expression was demonstrated in the dermis of normal skin (paraffin). 5 E-cadherin was also strongly expressed in epithelial cells of normal prostate, especially in areas of cell-cell contact (frozen). 3 Abnormal Tissues E-cadherin immunoreactivity has been demonstrated in a variety of abnormal cell types. 1-3,5-8,10,11 Table 1 summarizes expression of E- cadherin in abnormal tissues. Table 1. Abnormal Tissue Reactivity Tissue Type Positive and Negative Tissue Element Staining and Staining Pattern Bladder: Primary transitional cell carcinoma of the bladder a,b 13/40 positive, homogeneous (membranous) 13/40 positive, heterogeneous 14/40 negative High Grade (grade IIb and III): 10/24 positive Low Grade (grade I and IIa): 16/16 positive Superficial stage (Ta and Ti): 21/22 positive Invasive stage (T2, T3 and T4): 5/18 positive Breast cancer: Node negative b (without chemotherapy or hormonal therapy) 136/168 positive Breast carcinoma: Ductal a,b 55/87 a strong positive, majority of cells 29/87 a weaker positive, heterogeneous 14/24 b strong positive, majority of cells 10/24 b weaker positive, heterogeneous Breast carcinoma: Lobular a,b 3/21 a positive focal - very sparse intercellular membrane -or weak cytoplasmic 3/14 b positive, focal - very sparse intercellular membrane - or weak cytoplasmic Esophagus: Squamous cell carcinoma a 4/15 positive 10/15 positive, heterogeneous or weak Gastric carcinoma b 108/413 positive, homogeneous linear expression and comparable to normal gastric mucosa 95/413 positive, moderately reduced linear or dotted intercellular staining in 20-60% tumor cells 86/413 positive, highly reduced finely dotted intercellular staining in < 20% cells 124/413 negative or weak dotted immunoreactivity < 5% cells. Special pattern of E-cadherin expression was present in a small percentage of signet ring-cell carcinomas and of undifferentiated carcinomas, where a strong intracytoplasmic “plaque-like” expression of E-cadherin could be demonstrated, sometimes in combination with a very weak immunoreactivity at tumor-cell membrane. Endometriosis a 3/9 positive 6/9 positive, heterogeneous (105481-003) 303718EFG_001 p. 3/9 Skin: Melanocytic naevi b 20/20 positive membranous, superficial compartment of naevi and at the borders between naevus cell nests and keratinocytes of the surrounding epidermis. Junctional naevus cell nests were more heterogeneous than in the epidermal component or diffusely cytoplasmic. Melanocytic cells in the papillary dermis were negative. Skin: Malignant melanoma b 13/70 positive, membranous 30/70 positive, heterogeneous 11/70 cytoplasmic 16/70 negative Immunoreactivity associated with histological types of melanomas: 1/34 superficial spreading melanoma-positive, membranous 18/34 superficial spreading melanoma-positive, heterogeneous 8/34 superficial spreading melanoma-cytoplasmic 7/34 superficial spreading melanoma-negative 3/8 nodular melanoma-positive, heterogeneous 2/8 nodular melanoma-cytoplasmic 3/8 nodular melanoma-negative 4/9 lentigo malignant melanoma-positive, heterogeneous 1/9 lentigo malignant melanoma-cytoplasmic 4/9 lentigo malignant melanoma-negative 1/8 lentiginous melanoma-positive, membranous 5/8 lentiginous melanoma-positive, heterogeneous 2/8 lentiginous melanoma-negative 11/11 metastatic melanoma-positive, membranous Prostate cancer: Primary tumors a 44/84 positive, homogeneous 27/84 positive, heterogeneous 13/84 negative Metastatic lesions a 2/8 positive, homogeneous 5/8 positive, heterogeneous 1/8 negative Most differentiated cancers demonstrated strong and uniformly positive immunoreactivity at the cell-cell boundaries, whereas an increasing percentage of less well differentiated to poorly differentiated tumors demonstrated heterogeneous or negative immunoreactivity. a Testing was performed on cryostat sections b Testing was performed on paraffin-embedded formalin-fixed tissue sections.

Buffer: Monoclonal Mouse antibody provided in liquid form as tissue culture supernatant in 0.05 mol/L Tris-HCl, pH 7.2 and 0.015 mol/L sodium azide. This product contains stabilizing protein.

Lagerung: Store at 2-8 °C. Precautions: 1. For professional users. 2. This product contains sodium azide (NaN 3 ), a chemical highly toxic in pure form. At product concentrations, though not classified as hazardous, NaN 3 may react with lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent metal azide build-up in plumbing. 9 3. As with any product derived from biological sources, proper handling procedures should be used. 4. Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin. 5. Unused reagents should be disposed of according to local, State, and Federal regulations.

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.